아시아태평양의 신종 감염증 진단 시장 : 분석과 예측(2023-2033년)

“The Asia-Pacific Emerging Infectious Disease Diagnostics Market Expected to Reach $10.83 Billion by 2033.”

Introduction to Asia-Pacific Emerging Infectious Disease Diagnostics Market

The Asia-Pacific emerging infectious disease diagnostics market was valued at $4.41 billion in 2022 and is expected to reach $10.83 billion by 2033, growing at a CAGR of 8.65% between 2023 and 2033. A number of factors are driving the growing infectious disease diagnostics market's expansion in the Asia-Pacific area. The financial burden of infectious diseases, support from governments in the form of partnerships and financing, the growing demand for rapid and thorough testing, and developments in molecular diagnostics technology are some of these causes.

Market Introduction

In the APAC market, diagnostics for infectious diseases comprise a variety of approaches and procedures used to identify and find infectious agents in people who may be infected. These diagnostics are essential for prompt treatment decisions, accurate disease diagnosis, and the execution of public health initiatives.

Microbiological culture is one of the basic methods used in the diagnosis of infectious diseases. To isolate and identify certain pathogens, patient specimens are cultured on specialized growth media. Healthcare professionals can identify the causing organism and evaluate its antibiotic susceptibility by doing this.

Molecular diagnostics is a key strategy in the APAC industry. This entails detecting the genetic makeup of the infectious pathogen using methods like nucleic acid amplification tests (NAATs) and polymerase chain reaction (PCR). This enables the highly sensitive and specific identification of pathogens, even at low concentrations.

Market Segmentation:

Segmentation 1: by Application

• Laboratory Testing
• Point-of-Care Testing

Segmentation 2: by Technology

• Polymerase Chain Reaction (PCR)
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Next-Generation Sequencing (NGS)
• Immunodiagnostics
• Other Technologies

Segmentation 3: by Type of Infection

• Bacterial
• Viral
• Fungal
• Other Infections

Segmentation 4: by Disease Type

• Respiratory Infections
• Sexually Transmitted Infections (STIs)
• Gastrointestinal Infections
• Other Infections

Segmentation 5: by End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Other End Users

Segmentation 6: by Region

• Asia-Pacific - Japan, China, India, South Korea, Australia, Rest-of-Asia-Pacific

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The Asia-Pacific emerging infectious disease diagnostics market has been extensively segmented on the basis of various categories, such as application, technology, type of infection, disease type, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Asia-Pacific emerging infectious disease diagnostics market is fragmented, with several established as well as emerging players. Key players in the Asia-Pacific emerging infectious disease diagnostics market analyzed and profiled in the study involve established players that offer various kinds of molecular diagnostic tests for infectious diseases.

Table of Contents

1 Markets

• 1.1 Market Outlook
  • 1.1.1 Product Definition
  • 1.1.2 Inclusion and Exclusion Criteria
  • 1.1.3 Key Findings
• 1.2 Industry Outlook
  • 1.2.1 Market Overview
    • 1.2.1.1 Timeline of Emerging Technologies for Infectious Disease Diagnostics
    • 1.2.1.2 Advantages and Limitations of Emerging Infectious Disease Diagnostic Technologies
    • 1.2.1.3 Advantages and Limitations of Point-of-Care Emerging Infectious Disease Diagnostics
    • 1.2.1.4 Current Market Landscape of Emerging Infectious Disease Diagnostics
    • 1.2.1.5 Future Potential
      • 1.2.1.5.1 CRISPR
      • 1.2.1.5.2 NGS
      • 1.2.1.5.3 INAAT
      • 1.2.1.5.4 Digital PCR (dPCR)
  • 1.2.2 Patent Analysis
    • 1.2.2.1 By Year
    • 1.2.2.2 By Country/Organization
  • 1.2.3 Pipeline Analysis
  • 1.2.4 Impact of COVID-19 on Infectious Disease Diagnostics
    • 1.2.4.1 Post-COVID-19 Scenario: A Paradigm Shift to Home-Based Testing
  • 1.2.5 Supply Chain Analysis
• 1.3 Market Dynamics
  • 1.3.1 Impact Analysis
  • 1.3.2 Drivers
    • 1.3.2.1 Economic Burden of Infectious Diseases
    • 1.3.2.2 Government Support to Advance Research and Facilitate Early Diagnosis of Infectious Diseases Through Funding and Collaboration
    • 1.3.2.3 Increasing Demand for Point-of-Care (POC) and Syndromic Testing
    • 1.3.2.4 Technological Advancements in Molecular Diagnostics
      • 1.3.2.4.1 Isothermal Nucleic Acid Amplification Techniques (INAATs)
      • 1.3.2.4.2 Digital PCR
      • 1.3.2.4.3 CRISPR Technologies
  • 1.3.3 Restraints
    • 1.3.3.1 Poor Reimbursement for Molecular Diagnostic Tests for Infectious Diseases
    • 1.3.3.2 Erratic Trend in Infectious Disease Epidemic Outbreaks Globally
    • 1.3.3.3 Lack of an Established Framework for NGS-based Tests for Infectious Diseases
  • 1.3.4 Opportunities
    • 1.3.4.1 Potential of Molecular Diagnostic Tests in Low-Resource Settings
    • 1.3.4.2 Potential of Rapid Point-of-Care Tests in Managing Antimicrobial Resistance

2 Asia-Pacific

• 2.1 Asia-Pacific Emerging Infectious Disease Diagnostics Market
  • 2.1.1 Regulatory Framework
  • 2.1.2 Market Dynamics
    • 2.1.2.1 Impact Analysis
  • 2.1.3 Market Size and Forecast
    • 2.1.3.1 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Application)
    • 2.1.3.2 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Technology)
    • 2.1.3.3 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Type of Infection)
    • 2.1.3.4 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Disease Type)
    • 2.1.3.5 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by End User)
    • 2.1.3.6 Asia-Pacific Emerging Infectious Disease Diagnostics Market (by Country)
      • 2.1.3.6.1 Japan
        • 2.1.3.6.1.1 Market Dynamics
        • 2.1.3.6.1.2 Market Size and Forecast
        • 2.1.3.6.1.2.1 Japan Emerging Infectious Disease Diagnostics Market (by End User)
      • 2.1.3.6.2 China
        • 2.1.3.6.2.1 Market Dynamics
        • 2.1.3.6.2.2 Market Size and Forecast
        • 2.1.3.6.2.2.1 China Emerging Infectious Disease Diagnostics Market (by End User)
      • 2.1.3.6.3 Australia
        • 2.1.3.6.3.1 Market Dynamics
        • 2.1.3.6.3.2 Market Size and Forecast
        • 2.1.3.6.3.2.1 Australia Emerging Infectious Disease Diagnostics Market (by End User)
      • 2.1.3.6.4 South Korea
        • 2.1.3.6.4.1 Market Dynamics
        • 2.1.3.6.4.2 Market Size and Forecast
        • 2.1.3.6.4.2.1 South Korea Emerging Infectious Disease Diagnostics Market (by End User)
      • 2.1.3.6.5 India
        • 2.1.3.6.5.1 Market Dynamics
        • 2.1.3.6.5.2 Market Size and Forecast
        • 2.1.3.6.5.2.1 India Emerging Infectious Disease Diagnostics Market (by End User)
      • 2.1.3.6.6 Rest-of-Asia-Pacific
        • 2.1.3.6.6.1 Market Dynamics
        • 2.1.3.6.6.2 Market Size and Forecast
        • 2.1.3.6.6.2.1 Rest-of-Asia-Pacific Emerging Infectious Disease Diagnostics Market (by End User)

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Overview
  • 3.1.2 Corporate Strategies
    • 3.1.2.1 Mergers and Acquisitions
    • 3.1.2.2 Synergistic Activities
    • 3.1.2.3 Business Expansions and Funding
  • 3.1.3 Business Strategies
    • 3.1.3.1 Product Launches/Upgradations/Approvals
• 3.2 Market Share Analysis
• 3.3 Emerging Infectious Disease Diagnostics Ecosystem Active Players
• 3.4 Company Profiles
• 3.5 Company Snapshots
  • 3.5.1 CrisprBits
    • 3.5.1.1 Company Overview
    • 3.5.1.2 Role of CrisprBits in the Emerging Infectious Disease Diagnostics Market
    • 3.5.1.3 Key Developments